Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
INJECTION, SUSPENSION
**Posology and method of administration** Posology _Primary vaccination:_ The primary vaccination consists of 3 doses of 0.5 ml to be administered at intervals of at least four weeks and as per schedules 6, 10, 14 weeks; 2, 3, 4 months; 3, 4, 5 months; 2, 4, 6 months. All vaccination schedules including the WHO Expanded Program on Immunisation (EPI) at 6, 10, 14 weeks of age can be used whether or not a dose of hepatitis B vaccine has been given at birth. Where a dose of hepatitis B vaccine is given at birth; - Hexaxim can be used for supplementary doses of hepatitis B vaccine from the age of 6 weeks. If a second dose of hepatitis B vaccine is required before this age, monovalent hepatitis B vaccine should be used. - Hexaxim can be used for a mixed hexavalent/pentavalent/hexavalent combined vaccine immunisation schedule in accordance with official recommendations. The use of this vaccine should be in accordance with official recommendations. _Booster vaccination:_ After a 3-dose primary vaccination with Hexaxim, a booster dose should be given, preferably during the second year of life, at least 6 months after the last priming dose. Booster doses should be given in accordance with the official recommendations. As a minimum, a dose of Hib vaccine must be administered. After a 3-dose primary vaccination with Hexaxim (2, 3, 4 months; 3, 4, 5 months; 2, 4, 6 months) and in the absence of hepatitis B vaccination at birth, it is necessary to give a hepatitis B vaccine booster dose. Hexaxim can be considered for the booster. When a hepatitis B vaccine is given at birth, after a 3-dose primary vaccination, Hexaxim or a pentavalent DTaP-IPV/Hib vaccine can be administered for the booster. Hexaxim may be used as a booster in individuals who have previously been vaccinated with another hexavalent vaccine or a pentavalent DTaP-IPV/Hib vaccine associated with a monovalent hepatitis B vaccine. WHO-EPI schedule (6, 10, 14 weeks): After a WHO-EPI schedule, a booster dose should be given - As a minimum, a booster dose of polio vaccine should be given - In absence of hepatitis B vaccine at birth, a hepatitis B vaccine booster must be given - Hexaxim can be considered for the booster **Other paediatric population** The safety and efficacy of Hexaxim in children over 24 months of age have not been established. Method of administration Immunisation must be carried out by intramuscular (IM) injection. The recommended injection sites are the antero-lateral area of the upper thigh (preferred site) or the deltoid muscle in older children (possibly from 15 months of age). For instructions on handling, see section Special precautions for disposal and other handling – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.
INTRAMUSCULAR
Medical Information
**Therapeutic indications** Hexaxim (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks to 24 months of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by _Haemophilus influenzae_ type b (Hib). The use of this vaccine should be in accordance with official recommendations.
**Contraindications** History of an anaphylactic reaction after a previous administration of Hexaxim. Hypersensitivity to the active substances, to any of the excipients listed in section List of excipients – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_, to trace residuals (glutaraldehyde, formaldehyde, neomycin, streptomycin and polymyxin B), to any pertussis vaccine, or after previous administration of Hexaxim or a vaccine containing the same components or constituents. Vaccination with Hexaxim is contraindicated if the individual has experienced an encephalopathy of unknown aetiology, occurring within 7 days following prior vaccination with a pertussis containing vaccine (whole cell or acellular pertussis vaccines). In these circumstances pertussis vaccination should be discontinued and the vaccination course should be continued with diphtheria, tetanus, hepatitis B, poliomyelitis and Hib vaccines. Pertussis vaccine should not be administered to individuals with progressive neurologic disorder, uncontrolled epilepsy or progressive encephalopathy until treatment for the condition has been established, the condition has stabilised and the benefit clearly outweighs the risk.
J07CA09
diphtheria-haemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B
Manufacturer Information
SANOFI-AVENTIS SINGAPORE PTE. LTD.
Sanofi Pasteur Val de Reuil
Active Ingredients
DIPHTHERIA TOXOID
30 Lf (>= 20 IU)/0.5 mL
POLIOVIRUS (INACTIVATED) TYPE 3 (SAUKETT)
32 DU/0.5 mL
FILAMENTOUS HAEMAGGLUTININ
25 μg/0.5 mL
HAEMOPHILUS INFLUENZA TYPE B POLYSACCHARIDE (POLYRIBOSYLRIBITOL PHOSPHATE) CONJUGATED TO 22 - 36 μg TETANUS PROTEIN (PRP-T)
12 μg/0.5 mL
POLIOVIRIUS (INACTIVATED) TYPE 1 (MAHONEY)
40 DU/0.5 mL
PERTUSSIS TOXOID
25 μg/0.5 mL
POLIOVIRUS (INACTIVATED) TYPE 2 (MEF-1)
8 DU/0.5 mL
Documents
Package Inserts
Hexaxim injection PI.pdf
Approved: March 21, 2023
